RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

By
June 1, 2026
5 min

Dana-Farber

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

University of California, Los Angeles (UCLA) Health

Los Angeles, CA
Key Differentiators
- Oncology
#2

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Oncology
#3

Hale Family Center for Pancreatic Cancer Research

Boston, MA
Key Differentiators
- Pancreatic Cancer Research
#4

Gastrointestinal Cancer Center

Boston, MA
Key Differentiators
- Gastrointestinal Oncology
#5

American Society of Clinical Oncology (ASCO)

Alexandria, VA
Key Differentiators
- Oncology

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

Top Institutions in Oncology

University of California, Los Angeles (UCLA) Health

Dana-Farber Cancer Institute

Hale Family Center for Pancreatic Cancer Research

Gastrointestinal Cancer Center

American Society of Clinical Oncology (ASCO)

Original Source(s)

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

Related Content

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship